Sign in

CIK 0001641281 · <br>Emerging growth company

Bolt Biotherapeutics, Inc.

Sign in to watch
Ticker
BOLT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
472804636
Phone
650-665-9295
Business address
900 CHESAPEAKE DRIVE, REDWOOD CITY, CA, 94063
Former names
Bolt Therapeutics, Inc.
Open-market buys, last 90 days
$319,000
in 1 filing
Open-market sales, last 90 days
$128,281
in 3 filings

Net +$190,719. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Coastlands Capital LP +$319K 10% owner 1 filing
  2. Quinn William P. −$58K President, CEO and CFO sold 41% of stake
  3. Yonehiro Grant −$44K Chief Operating Officer sold 43% of stake
  4. Nemec Sarah −$26K Senior VP, Finance and PAO sold 31% of stake
Date Insider Transaction Shares Price Value Owned after
2021-02-09 ENGLEMAN EDGAR Director Option exercise · Warrant (Right to Buy) −40,953 0
2021-02-09 ENGLEMAN EDGAR Director Conversion · Series B Preferred Stock −150,802 0
2021-02-09 ENGLEMAN EDGAR Director Conversion · Series C- 1 Preferred Stock −43,901 0
2021-02-09 ENGLEMAN EDGAR Director Conversion · Series C- 2 Preferred Stock −47,718 0
2021-02-09 ENGLEMAN EDGAR Director Option exercise · Warrant (Right to Buy) −5,655 0
2021-02-09 Quinn William P. Chief Financial Officer Purchase +1,200 $20.00 $24K 13,898
2021-02-09 Schatzman Randall C Chief Executive Officer Purchase +1,500 $20.00 $30K 1,500
2021-02-09 Sofinnova Venture Partners X, L.P. 10% owner Conversion +1,104,209 1,104,209
2021-02-09 Sofinnova Venture Partners X, L.P. 10% owner Conversion +1,200,228 2,304,437
2021-02-09 Sofinnova Venture Partners X, L.P. 10% owner Purchase +450,000 $20.00 $9.0M 2,754,437
2021-02-09 Sofinnova Venture Partners X, L.P. 10% owner Conversion · Series C-1 Preferred Stock −1,104,209 0
2021-02-09 Sofinnova Venture Partners X, L.P. 10% owner Conversion · Series C-2 Preferred Stock −1,200,228 0
2021-02-04 Yonehiro Grant Chief Business Officer Grant or award · Stock Option (Right to Buy) +100,000 100,000
2021-02-04 Perez Edith A. Chief Medical Officer Grant or award · Stock Option (Right to Buy) +100,000 100,000
2021-02-04 Dornan David Chief Scientific Officer Grant or award · Stock Option (Right to Buy) +110,000 110,000
2021-02-04 Quinn William P. Chief Financial Officer Grant or award · Stock Option (Right to Buy) +100,000 100,000
2021-02-04 Schatzman Randall C Chief Executive Officer Grant or award · Stock Option (Right to Buy) +340,000 340,000

Page 17 of 17 · 337 trades